CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,001 enrolled
Drug / intervention
Epiduo® Forte Gel +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02651220
NCT02651220Phase 3Completed
CompareCT.gov

Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris

Actavis Inc.·interventional·Posted Jan 8, 2016·Updated Jun 23, 2020

In Brief

A Phase 3 clinical trial evaluating Epiduo® Forte Gel, Adapalene and Benzoyl Peroxide Gel, and 1 other intervention for Acne. Completed, enrolled 1,001 participants across 20 sites in 2 countries.

Detailed Summary

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of adapalene and benzoyl peroxide gel, 0.3%/2.5% (Actavis Laboratories UT, Inc.) to Epiduo® Forte (adapalene and benzoyl peroxide) gel 0.3%/2.5% (Galderma) in the treatment of Acne Vulgaris

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne
CountriesBelize, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 8, 2016
Enrollment StartNov 1, 2015
Primary CompletionApr 1, 2016
Study CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 10.5 years ago

Interventions

Epiduo® Forte Geldrug

Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w

Adapalene and Benzoyl Peroxide Geldrug

Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w

placebo geldrug

vehicle used as placebo